{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=14",
    "query": {
      "intervention": "Control Capsules",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 2901,
    "total_pages": 291,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T14:44:54.911Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03428464",
      "title": "Bicarbonate Administration in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Transplant; Complications",
        "Metabolic Acidosis"
      ],
      "interventions": [
        {
          "name": "Sodium Bicarbonate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-12-05",
      "completion_date": "2020-03-25",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03428464"
    },
    {
      "nct_id": "NCT00560183",
      "title": "Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Q8003 (morphine sulfate and oxycodone hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QRxPharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 256,
      "start_date": "2007-11",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2012-05-17",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "Altoona",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00560183"
    },
    {
      "nct_id": "NCT01167881",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1549,
      "start_date": "2010-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01167881"
    },
    {
      "nct_id": "NCT02149160",
      "title": "Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Granulin Mutation"
      ],
      "interventions": [
        {
          "name": "FRM-0334",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FORUM Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-03-23",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Orlando, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02149160"
    },
    {
      "nct_id": "NCT05873062",
      "title": "Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myoclonus Epilepsies, Progressive"
      ],
      "interventions": [
        {
          "name": "AUT00201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Autifony Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-05-12",
      "completion_date": "2024-05-01",
      "has_results": true,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05873062"
    },
    {
      "nct_id": "NCT05036512",
      "title": "A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "GBT021601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 129,
      "start_date": "2020-12-09",
      "completion_date": "2023-02-07",
      "has_results": false,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05036512"
    },
    {
      "nct_id": "NCT04251182",
      "title": "Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "15mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "30 mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "45 mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "T3D Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 250,
      "start_date": "2021-03-01",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04251182"
    },
    {
      "nct_id": "NCT03660488",
      "title": "Cefixime for Alternative Syphilis Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Syphilis",
        "Early Syphilis"
      ],
      "interventions": [
        {
          "name": "Cefixime 400 milligram Oral Capsule [Suprax]",
          "type": "DRUG"
        },
        {
          "name": "Benzathine Penicillin G",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2018-09-03",
      "completion_date": "2021-01-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 10,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Oakland, California + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03660488"
    },
    {
      "nct_id": "NCT00928083",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria Falciparum",
        "Malaria Vivax",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "OZ439 50mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 100mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1600mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg aqueous dispersion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicines for Malaria Venture",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2009-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00928083"
    },
    {
      "nct_id": "NCT01389596",
      "title": "A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy, Partial Seizures"
      ],
      "interventions": [
        {
          "name": "Pregabalin add-on therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "4 Years to 16 Years"
      },
      "enrollment_count": 295,
      "start_date": "2011-09-27",
      "completion_date": "2016-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-01-20",
      "last_synced_at": "2026-10-23T14:44:54.911Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01389596"
    }
  ]
}